Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0189582
Abstract: Bevacizumab combined with cytotoxic chemotherapy is the backbone of metastatic colorectal cancer (mCRC) therapy; however, its treatment efficacy is hampered by therapeutic resistance. Therefore, understanding the mechanisms underlying bevacizumab resistance is crucial to increasing the… read more here.
Keywords: involved bevacizumab; genes pathways; colorectal cancer; bevacizumab resistant ... See more keywords